Neo-adjuvant Chemotherapy-Induced Neutropenia Is Associated with Histological Responses and Outcomes after the Resection of Colorectal Liver Metastases
- 29 Downloads
Neutropenia, the major adverse event in chemotherapy, is associated with favourable clinical outcome in several solid tumours. We aimed to investigate the predictive value of neo-adjuvant chemotherapy (NAC)–induced neutropenia for the pathological response and prognosis in colorectal liver metastases (CRLM) patients.
A retrospective review was performed in 141 CRLM patients receiving NAC followed by liver resection. A logistic regression was applied to analyse potential predictors. A Cox proportional hazards analysis was used to analyse survival.
Neutropenia due to NAC was observed in 42.6% (60/141) of all patients, and grade 3/4 neutropenia was noted in 31.7% (19/60). A pathological response (tumour regression grade (TRG) 1–3) was reported in 46.1% (65/141) of patients. Multivariate analysis showed that neutropenia significantly predicted the favourable pathological response (OR = 3.718, 95% CI 1.716–8.329, P = 0.001), as well as targeted therapy, good differentiation and preoperative CEA < 10 ng/ml as independent predictors of favourable histological response. Of the patients, 54.6% (77/141) had postoperative complications, including 28 major complications (28/77, 36.4%). Severe neutropenia significantly predicted postoperative major complications in multivariate analysis (OR = 4.077, 95% CI 1.184–14.038, P = 0.026). Compared to patients without neutropenia, patients with neutropenia had significantly better progression-free survival (PFS) (P = 0.007; mPFS, 10.2 months vs. 6.7 months). Patients with histological response had significantly better PFS than patients with no histological response (P = 0.001; mPFS, 10.0 months vs. 5.5 months). According to multivariate analyses, neutropenia was a significant predictor for better PFS (HR = 0.613, 95% CI 0.406–0.925, P = 0.020) but not OS.
For CRLM patients receiving NAC followed by liver resection, NAC-induced neutropenia was a significant predictor of favourable pathological response, postoperative major complications and better prognosis, which makes it useful for CRLM patients in guiding treatment approaches and prognosis assessments.
KeywordsColorectal cancer liver metastasis Liver resection Neo-adjuvant chemotherapy Neutropenia Histological response Prognosis
We are grateful to Dr. Xingjin Wu for critically reading the manuscript and for her valuable comments.
All authors have made substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; drafting the work or revising, and final approval of the version to be published.
Compliance with Ethical Standards
Conflicts of Interest
All authors have no conflicts of interests to disclose.
This study was approved by the Institutional Review Board of the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. All patients provided written informed consent.
Author names in bold designate shared co-first authorship
- 2.Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, Ychou M, Rougier P. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. European journal of cancer (Oxford, England : 1990). 2006;42(14):2212–21. https://doi.org/10.1016/j.ejca.2006.04.012.Google Scholar
- 5.Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(9):2038–48. https://doi.org/10.1200/jco.2005.00.349.Google Scholar
- 6.Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet (London,England).2008;371(9617):1007–16. https://doi.org/10.1016/s0140-6736(08)60455-9.Google Scholar
- 7.Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, Delpero JR, Rivoire M, Quenet F, Portier G, Nordlinger B. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer chemotherapy and pharmacology. 2008;62(2):195–201. https://doi.org/10.1007/s00280-007-0588-3.Google Scholar
- 8.Blazer DG, 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(33):5344–51. https://doi.org/10.1200/jco.2008.17.5299.Google Scholar
- 9.Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA, Abdalla EK, Capussotti L, Vauthey JN. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Annals of surgical oncology. 2010;17(11):2870–6. https://doi.org/10.1245/s10434-010-1166-1.Google Scholar
- 10.Carrasco J, Gizzi M, Pairet G, Lannoy V, Lefesvre P, Gigot JF, Hubert C, Jouret-Mourin A, Humblet Y, Canon JL, Sempoux C, Chapaux X, Danse E, Tinton N, Navez B, Van den Eynde M. Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. British journal of cancer. 2015;113(9):1298–304. https://doi.org/10.1038/bjc.2015.321.Google Scholar
- 11.Pang TC, Spiro C, Ramacciotti T, Choi J, Drummond M, Sweeney E, Samra JS, Hugh TJ. Complications following liver resection for colorectal metastases do not impact on long-term outcome. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2015;17(2):185–93. https://doi.org/10.1111/hpb.12327.Google Scholar
- 14.Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, Manzione L, Illiano A, Barbera S, Robbiati SF, Frontini L, Piazza E, Ianniello GP, Veltri E, Castiglione F, Rosetti F, Gebbia V, Seymour L, Chiodini P, Perrone F. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. The Lancet Oncology. 2005;6(9):669–77. https://doi.org/10.1016/s1470-2045(05)70255-2.Google Scholar
- 15.Sunaga T, Suzuki S, Kogo M, Kurihara T, Kaji S, Koike N, Harada N, Suzuki M, Kiuchi Y. The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy. European journal of cancer care. 2014;23(3):394–400. https://doi.org/10.1111/ecc.12120.Google Scholar
- 16.Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A, Yoshino T. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC cancer. 2016;16:467. https://doi.org/10.1186/s12885-016-2491-y.Google Scholar
- 17.Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. British journal of cancer. 2007;97(1):37–42. https://doi.org/10.1038/sj.bjc.6603831.Google Scholar
- 21.Han HS, Rybicki LA, Thiel K, Kalaycio ME, Sobecks R, Advani A, Brown S, Sekeres MA. White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia. Leukemia & lymphoma. 2007;48(8):1561–8. https://doi.org/10.1080/10428190701474373.Google Scholar
- 24.Robb WB, Messager M, Gronnier C, Tessier W, Hec F, Piessen G, Mariette C. High-grade toxicity to neoadjuvant treatment for upper gastrointestinal carcinomas: what is the impact on perioperative and oncologic outcomes? Annals of surgical oncology. 2015;22(11):3632–9. https://doi.org/10.1245/s10434-015-4423-5.Google Scholar
- 27.Institute NC. Common terminology criteria for adverse events (CTCAE), version 4.0. 2010. http://evs.nci.nih.gov/%0Aftp1/CTCAE/CTCAE_ 4.03_2010-06-14_QuickReference_5x7.pdf.
- 28.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England : 1990). 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.Google Scholar
- 29.Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Majno PE, Soubrane O, Chaussade S, Mentha G, Terris B. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Annals of oncology : official journal of the European Society for Medical Oncology. 2007;18(2):299–304. https://doi.org/10.1093/annonc/mdl386.Google Scholar
- 30.Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of surgery. 2004;240(2):205–13.Google Scholar
- 31.Standish LJ, Torkelson C, Hamill FA, Yim D, Hill-Force A, Fitzpatrick A, Olsen M, Schildt S, Sweet E, Wenner CA, Martzen MR. Immune defects in breast cancer patients after radiotherapy. Journal of the Society for Integrative Oncology. 2008;6(3):110–21.Google Scholar
- 33.Konishi H, Fujiwara H, Shiozaki A, Hiramoto H, Kosuga T, Komatsu S, Ichikawa D, Okamoto K, Otsuji E. Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy. International journal of clinical oncology. 2016;21(1):95–101. https://doi.org/10.1007/s10147-015-0875-7.Google Scholar
- 35.Okuno M, Hatano E, Nishino H, Seo S, Taura K, Uemoto S. Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases? A systematic review. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2017;43(6):1003–12. https://doi.org/10.1016/j.ejso.2016.08.019.Google Scholar
- 36.Stremitzer S, Stift J, Singh J, Starlinger P, Gruenberger B, Tamandl D, Gruenberger T. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2015;41(7):868–74. https://doi.org/10.1016/j.ejso.2015.03.223.Google Scholar
- 37.Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010;16(1):320–9. https://doi.org/10.1158/1078-0432.ccr-09-1555. Google Scholar